PATIENT SUPPORT SERVICES
Natalie*
Person with PH1

*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

Alnylam Assist® provides support services for patients throughout treatment with OXLUMO® (lumasiran).

 

This program offers support services for patients being treated with OXLUMO. If you would like to access OXLUMO for one of your patients through Alnylam Assist®, the first step is completing the Start Form.

Image
Alnylam Assist® Logo

Alnylam Assist® can help PH1 patients prescribed OXLUMO®:

Start treatment with OXLUMO.

Understand their benefits and coverage, as well as eligibility for financial assistance options such as the Commercial Copay Program.*

Connect with Alnylam for ongoing information and product support.

Learn more about PH1 and treatment with OXLUMO.

An Alnylam Field Reimbursement Director can provide education about billing, coding, coverage, and reimbursement for OXLUMO.

Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist® Commercial Copay Program. Out-of-pocket costs for the administration of OXLUMO will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

Image

Electronic Start Form

Fill out the Electronic Start Form online with your patient.

Get Started

Image

Downloadable Start Form

Print the Start Form, complete it with your patient, then fax it to 1-833-256-2747. 

Download

Image

DocuSign Start Form

Begin the Start Form, then send it to your patient via email to complete their portion.

Begin Start Form

See DocuSign Instructions

What happens next?

  1. An Alnylam Case Manager will reach out to you and your patient within 2 business days of receiving the completed Start Form.
  2. Alnylam Assist® will help your patient access OXLUMO.
Image

Alnylam Assist® offers support services for your patients prescribed OXLUMO:

Image

Benefits verification Help determining patient-specific coverage. Within 2 business days of receiving the Start Form, an Alnylam Case Manager will reach out to your patient to begin discussing their insurance benefits.

Image

Financial assistance Alnylam is committed to making OXLUMO available to those who need it. When starting treatment, an Alnylam Case Manager will help determine eligibility for one of Alnylam's financial assistance programs.a

Alnylam Assist® Patient Assistance Program (PAP): Provides OXLUMO at no cost to eligible patients, primarily the uninsured, who meet specified financial criteria.

Alnylam Assist® Commercial Copay Programb: Covers certain out-of-pocket costs for eligible patients with commercial insurance.

Image

Patient education Disease education and product information for patients and their families through trained Alnylam Patient Education Liaisons (PELs)

  • The purpose of Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers
  • PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice
  • All diagnosis and treatment decisions should be made by the treating physician and their patient
Image

Field Reimbursement Directors Alnylam Field Reimbursement Directors are available to answer coverage, coding, and reimbursement-related questions about Alnylam products.

Tell Me More About Alnylam Assist®

Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist® Commercial Copay Program. Out-of-pocket costs for the administration of OXLUMO will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

OXLUMO™ (lumasiran) Patient Brochure Preview

Downloadable patient brochure

A guide to help your patients better understand their condition and navigate treatment with OXLUMO.

OXLUMO® (lumasiran) Patient Brochure PreviewDownload the OXLUMO patient brochure for more information.

Download

Image

WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?

Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.

Let's Connect

Patient advocacy organizations

Help your patient expand their network and stay informed by connecting them with independent patient advocacy organizations.

Image
American Kidney Fund Logo

Visit Site

Image
National Kidney Foundation Logo

Visit Site

Image
Oxalosis and Hyperoxaluria Foundation Logo

Visit Site

We hope you find the resources mentioned here helpful. Alnylam Pharmaceuticals is not affiliated with any of these organizations. By listing these resources, Alnylam Pharmaceuticals is not endorsing any particular service or group, and we are not responsible for the content of these sites or services. They are provided for informational purposes and should not replace a doctor’s medical advice.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common (≥20%) adverse reaction reported in patients treated with OXLUMO was injection site reaction. Injection site reactions included erythema, swelling, pain, hematoma, pruritus, and discoloration.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.